Using NMR to Design Peptides You Can Take by Mouth: A New Strategy for Oral Peptide Drugs
Researchers developed an NMR-based method to identify where to chemically modify cyclic peptides, achieving 33% oral bioavailability in rats — a major step toward oral peptide drugs.
Quick Facts
What This Study Found
The researchers used NMR temperature coefficients to rapidly identify exposed amide bonds in cyclic peptides — the spots most vulnerable to water and therefore most in need of protection. By selectively N-methylating these positions, they created peptides with improved membrane permeability.
Five leucine-rich peptide scaffolds were tested with various N-methylation patterns. The most promising derivative (peptide 15) achieved 33% oral bioavailability in a rat model, validated through in vivo testing. The approach was further validated by explaining the known oral bioavailability of a somatostatin analog. Membrane permeability was confirmed using both parallel artificial membrane permeability assay (PAMPA) and Caco-2 cell assays before moving to animal testing.
Key Numbers
How They Did This
The team used NMR spectroscopy to measure temperature coefficients of amide protons in cyclic peptides, which reveals which amide bonds are solvent-exposed versus shielded by intramolecular hydrogen bonds. Exposed amides were selectively N-methylated to reduce water interaction and improve membrane crossing. Membrane permeability was assessed in vitro using PAMPA and Caco-2 cell assays. The top candidate was then tested in vivo in a Wistar rat model to measure actual oral bioavailability.
Why This Research Matters
Most peptide drugs today require injection because they can't survive oral administration. If peptides could be taken as pills, it would transform treatment for conditions like diabetes, growth disorders, and many others. This study provides a faster, more practical method for designing orally available peptides than the traditional approach of solving full 3D structures — potentially accelerating the development of oral peptide therapeutics across the pharmaceutical industry.
The Bigger Picture
The oral bioavailability problem is arguably the single biggest barrier limiting peptide therapeutics. While injectable peptides like semaglutide and insulin have been hugely successful, the pharmaceutical industry has invested billions trying to make them orally available. This NMR-guided N-methylation approach, published in PNAS by a team including researchers from Pfizer (Liras and Price), represents a significant methodological advance that has influenced subsequent peptide drug design efforts. The success of oral semaglutide (Rybelsus), approved in 2019, shows that oral peptide delivery is commercially viable — methods like this one help expand the approach to other peptide drugs.
What This Study Doesn't Tell Us
The 33% oral bioavailability was demonstrated in rats, which may not directly translate to humans due to differences in gut physiology and metabolism. The peptide scaffolds tested were leucine-rich model peptides without therapeutic targets — applying this approach to bioactive peptides with specific targets could introduce additional constraints. The study focused on membrane permeability as the main barrier to oral availability, but enzymatic degradation and first-pass metabolism are also important factors not fully addressed.
Questions This Raises
- ?Can this NMR-guided N-methylation approach be successfully applied to therapeutically active peptides without compromising their biological activity?
- ?Would the 33% oral bioavailability seen in rats hold up in larger animal models or human pharmacokinetic studies?
- ?How does this method compare in speed and cost to computational approaches for predicting oral peptide bioavailability?
Trust & Context
- Key Stat:
- 33% oral bioavailability The best N-methylated cyclic peptide achieved 33% oral bioavailability in rats — meaning a third of the swallowed dose reached the bloodstream, a strong result for a peptide.
- Evidence Grade:
- This is a well-designed preclinical methodology study published in PNAS, combining NMR structural analysis with in vitro permeability assays and in vivo rat pharmacokinetics. The evidence is strong for the methodological approach but remains preclinical — the peptides tested were model compounds, not therapeutic candidates.
- Study Age:
- Published in 2014, this study is over a decade old but remains highly relevant. It was ahead of its time — oral peptide delivery has since become one of the hottest areas in pharmaceutical development, with oral semaglutide approved in 2019.
- Original Title:
- Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients.
- Published In:
- Proceedings of the National Academy of Sciences of the United States of America, 111(49), 17504-9 (2014)
- Authors:
- Wang, Conan K(2), Northfield, Susan E(2), Colless, Barbara, Chaousis, Stephanie, Hamernig, Ingrid, Lohman, Rink-Jan, Nielsen, Daniel S, Schroeder, Christina I, Liras, Spiros, Price, David A, Fairlie, David P, Craik, David J
- Database ID:
- RPEP-02536
Evidence Hierarchy
Frequently Asked Questions
Why can't most peptide drugs be taken as pills?
Peptides are essentially small proteins, and the digestive system is designed to break down proteins. Most peptides get destroyed by stomach acid and digestive enzymes before they can be absorbed into the bloodstream. They also have difficulty crossing the intestinal membrane because of their size and chemical properties. This study addresses the membrane-crossing problem by chemically modifying peptides to make them more permeable.
What is N-methylation and how does it help?
N-methylation is the addition of a small methyl group (-CH₃) to specific nitrogen atoms in the peptide backbone. This caps exposed amide bonds that would otherwise interact with water, making the peptide less water-loving and more able to cross the fatty cell membranes of the intestinal lining. The key innovation here is using NMR to quickly figure out which positions to methylate.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02536APA
Wang, Conan K; Northfield, Susan E; Colless, Barbara; Chaousis, Stephanie; Hamernig, Ingrid; Lohman, Rink-Jan; Nielsen, Daniel S; Schroeder, Christina I; Liras, Spiros; Price, David A; Fairlie, David P; Craik, David J. (2014). Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients.. Proceedings of the National Academy of Sciences of the United States of America, 111(49), 17504-9.
MLA
Wang, Conan K, et al. "Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients.." Proceedings of the National Academy of Sciences of the United States of America, 2014.
RethinkPeptides
RethinkPeptides Research Database. "Rational design and synthesis of an orally bioavailable pept..." RPEP-02536. Retrieved from https://rethinkpeptides.com/research/wang-2014-rational-design-and-synthesis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.